Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-05-12

Clinical Trial Update: Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood [Phase 1]

View source ↗

Summary

Phase 1 study comparing subcutaneous versus intravenous administration of epratuzumab in systemic lupus erythematosus has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Epratuzumab (epratuzumab)

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED